Merck Announces Emerging Biotech Grant Program Winners

Merck Emerging Biotech Grant Programs
Share It On:

2nd November 2024, Kathmandu

Merck, a leading science and technology company, today announced the winners of its Emerging Biotech (EB) Grant Program in Asia Pacific.

Merck Emerging Biotech Grant Program

The Award is designed to support biotech startups with resources to enable emerging companies to discover, develop, optimize, and commercialize therapeutics faster and more efficiently.

“Merck is committed to supporting exceptional biotech companies to both kickstart and streamline their journey from discovery to manufacturing with our grant program,” said Chua Keng Hock, Senior Vice President, of Process Solutions Asia Pacific, Life Science business of Merck. “We recognize the complexities involved in delivering next-generation therapies to the market. Merck’s EB Grant is designed to expedite the development of treatments that address critical unmet medical needs.”

The award recipients are:

Country Grand Prize Winner Finalist Prize Winners Special Mention
Australia & New Zealand Southern RNA for enabling the manufacturing of mRNA for personalized medicines Institute for Drug Technology for enabling the manufacturing of antibody-drug conjugates.

Psaio for developing bispecific antibodies targeting prostate-specific antigen to treat prostate cancer.

Kimer Med for developing

a family of broad-spectrum antiviral biologics to treat infectious diseases, and for pandemic protection.

Taiwan HanchorBio for developing clinical-stage and next-generation immuno-oncology therapies through innovation in cutting-edge designer biologics with novel, multi-functional modalities. Pell Biomed Technology for developing more efficient and cost-effective gene-modified cell therapies.

Glyconex for glycan-directed cancer therapies including antibody-drug conjugates to treat a range of solid tumors such as gastrointestinal cancers.

Shine-On BioMedical for developing targeted exosomes as a platform for drug delivery as well as tri-specific antibody for cancer treatment.

Merck experts selected the winning submissions based on the scientific and societal merit of the therapy in development and process challenges and expertise gaps that may impact ongoing development. In-kind technologies and services from Merck will be awarded to the winners in Australia & New Zealand and Taiwan to help solve these challenges.

Merck first started the EB grant program in 2014 in the United States and has expanded its reach to include Europe, China, South Korea and Taiwan in recent years. In 2024, the EB Grant was extended to Australia & New Zealand and is open to Taiwan and South Korea (the winners for South Korea were announced in July 2024). To date, Merck’s EB Grant program has awarded technologies and consultation to over 40 biotechnology companies around the world, supporting their efforts to improve patient outcomes for various diseases such as cancer, brain tumors, osteoarthritis, and cardiovascular disorders.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare, and electronics. Around 63,000 employees work to make a positive difference in millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

For more: Merck Emerging Biotech Grant Program


Share It On:

Recent Posts

Kumari Bank Promoter Share Sale: Eligibility, Application Process, and Price

Kumari Bank Promoter Share Sale: Eligibility, Application Process, and Price

Share It On:21st November, Kathmandu Kumari Bank Limited has officially declared its intention to sell a substantial number of promoter

Up to NPR 150 Cashback on Nepal Telecom and Ncell Services with Namaste Pay

Up to NPR 150 Cashback on Nepal Telecom and Ncell

Share It On:21st November, Kathmandu Namaste Pay has unveiled an exciting new campaign to reward its users with cashback on

Ncell introduces innovative feature, enabling customers to convert voice to data or data to voice services

Ncell introduces innovative feature, enabling customers to convert voice to

Share It On:21st November, Kathmandu Ncell customers can enjoy an innovative feature that allows them to convert or exchange remaining

Genese Solution’s G-TEC: Empowering Women in Tech and Creating a Diverse Tech Workforce in Nepal

Genese Solution’s G-TEC: Empowering Women in Tech and Creating a

Share It On:21st November 2024, Kathmandu Genese Solution – a value IT consulting company, and Kageshwori Manohara municipality, have joined

Shikhar Insurance: Celebrating 20 Years of Service and Commitment to Nepali Customers

Shikhar Insurance: Celebrating 20 Years of Service and Commitment to

Share It On:21st November 2024, Kathmandu Shikhar Insurance had a grand celebration for their 20th Anniversary. On the occasion of

India’s Generative AI Startups: A Comprehensive Look at 2024’s Key Trends and Investments

India’s Generative AI Startups: A Comprehensive Look at 2024’s Key

Share It On:21st November 2024, Kathmandu As 2024 draws to a close, India’s generative AI ecosystem stands out as a